Clinical trials: Refractory Acute Myeloid Leukemia, open to volunteers
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT07012044
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 15 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT06177067
- Testing
- Revumenib, Venetoclax, Azacitidine
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute Leukemia
A Study of Revumenib and Mezigdomide in People With Leukemia
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
- Conditions
- Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT07356154
- Testing
- Revumenib, Mezigdomide
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia
This is a single-arm, single-center clinical study to assess the efficacy and safety of Mitoxantrone Hydrochloride Liposome combined with cladribine and sotoraclib in patients with relapsed/refractory acute myeloid leukemia…
- Trial name
- NCT07874737
- Testing
- Mitoxantrone Hydrochloride Liposome+cladribine+sotoraclib
- Volunteers
- 20 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory…
- Trial name
- NCT07355335
- Testing
- Ziftomenib, Mezigdomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT06017258
- Testing
- CD371-specific/YSNVz/I-18 CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03630991
- Testing
- Edetate Calcium Disodium, Multivitamin, Succimer
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety.
- Trial name
- NCT06786533
- Testing
- Anti-FLT3 CAR-T cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hemogenyx Pharmaceuticals LLC
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT03383575
- Testing
- Azacitidine, Enasidenib, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT05857969
- Testing
- Functional Precision Medicine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Florida International University
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia
- Trial name
- NCT06247787
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 19 sites in United States
- Volunteers
- 36 people
- Sponsor
- Children's Oncology Group
Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY035 cell injection in the treatment of patients with CD7-positive relapsed or…
- Conditions
- Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
- Trial name
- NCT07784309
- Testing
- HY035 cell injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
- Trial name
- RESOLVE (NCT02203903)
- Testing
- Tumor associated antigen lymphocytes (TAA-T)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Catherine Bollard
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
- Trial name
- IMPACT STREAM (NCT06459024)
- Testing
- Registration into the STREAM platform
- Where
- 40 sites in Germany, Italy and 4 more
- Volunteers
- 4,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+ acute myeloid leukemia (AML) that has come back after a period of…
- Trial name
- NCT06609928
- Testing
- FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia)
PRAISE-IR Versus CIBMTR Controls
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07717164
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Miltenyi Biomedicine GmbH
Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Relapsed or refractory acute leukemia (R/R AL) is a life-threatening blood cancer with poor outcomes and limited treatment options.
- Conditions
- Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Trial name
- R/R AL (NCT07696481)
- Testing
- PID23 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhujiang Hospital